NASDAQ:PCVX Vaxcyte Q1 2026 Earnings Report $58.27 +2.06 (+3.66%) Closing price 04:00 PM EasternExtended Trading$57.71 -0.56 (-0.96%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vaxcyte EPS ResultsActual EPS-$2.30Consensus EPS -$1.74Beat/MissMissed by -$0.56One Year Ago EPS-$1.04Vaxcyte Revenue ResultsActual RevenueN/AExpected Revenue$12.50 millionBeat/MissN/AYoY Revenue GrowthN/AVaxcyte Announcement DetailsQuarterQ1 2026Date5/6/2026TimeAfter Market ClosesConference Call DateWednesday, May 6, 2026Conference Call Time4:00PM ETUpcoming EarningsVaxcyte's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vaxcyte Earnings HeadlinesVaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says 1 minute ago | finance.yahoo.comVaxcyte (NASDAQ:PCVX) Stock Rating Reaffirmed as "Buy" by Needham & Company LLCSeptember 27 at 1:36 AM | americanbankingnews.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This past May, flooding hit the same complex again, and in July Cigar Lake went down a second time, disrupting the world's largest high-grade uranium mine. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.September 28 at 1:00 AM | Digest Publishing (Ad)Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 23, 2026 | americanbankingnews.comVaxcyte (PCVX) Dropped, So What Is Driving Attention Now?September 21, 2026 | finance.yahoo.comVaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test NearsSeptember 17, 2026 | finance.yahoo.comSee More Vaxcyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email. Email Address About VaxcyteVaxcyte (NASDAQ:PCVX) is a clinical-stage biotechnology company focused on developing vaccines to prevent serious bacterial infections. The company’s lead programs target pneumococcal disease, which can cause pneumonia, meningitis, bloodstream infections and other invasive illnesses. Vaxcyte is developing broad-spectrum pneumococcal conjugate vaccine candidates designed to protect against a wide range of bacterial serotypes. Vaxcyte’s pipeline has included VAX-24, an investigational 24-valent pneumococcal conjugate vaccine, and VAX-31, a next-generation candidate designed to cover 31 serotypes. The company also applies its cell-free protein synthesis and conjugation technologies to support the development of vaccines for additional bacterial pathogens. Founded in 2016 as SutroVax and later renamed Vaxcyte, the company is headquartered in San Carlos, California. Its programs are developed through clinical research and collaborations involving sites and participants in the United States and other regions. Grant Pickering, Ph.D., serves as Vaxcyte’s president and chief executive officer.View Vaxcyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
